FEMY (Femasys) COGS-to-Revenue : 0.34 (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Femasys COGS-to-Revenue?

Femasys's Cost of Goods Sold for the three months ended in Mar. 2025 was $0.12 Mil. Its Revenue for the three months ended in Mar. 2025 was $0.34 Mil.

Femasys's COGS to Revenue for the three months ended in Mar. 2025 was 0.34.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Femasys's Gross Margin % for the three months ended in Mar. 2025 was 65.69%.

Femasys COGS-to-Revenue Historical Data

The historical data trend for Femasys's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Femasys COGS-to-Revenue Chart

Femasys Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.30

0.31

0.37

0.35

0.33

Femasys Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
COGS-to-Revenue	Get a 7-Day Free Trial															0.32	0.33	0.34	0.33	0.34

Femasys COGS-to-Revenue Calculation

Femasys's COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.545	/	1.629
	=	0.33

Femasys's COGS to Revenue for the quarter that ended in Mar. 2025 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.117	/	0.341
	=	0.34

Femasys (NAS:FEMY) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Femasys's Gross Margin % for the three months ended in Mar. 2025 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.117 / 0.341
	=	65.69 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Femasys COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Femasys's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Femasys Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Femasys Inc (NAS:FEMY) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

3950 Johns Creek Court, Suite 100, Suwanee, GA, USA, 30024

Website

https://www.femasys.com

Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.

Executives

Keith J Kendall	director	30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alistair Milnes	director	C/O BICYCLE THERAPEUTICS PLC, B900, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Christine E Thomas	officer: SVP, Regulatory & Clinical	2836 SW 117TH STREET, GAINESVILLE FL 32606
Dov Elefant	officer: Chief Financial Officer	EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Wendy Perrow	director	C/O BIOANALYTICAL SYSTEMS, INC., 2701 KENT AVENUE, WEST LAFAYETTE IN 47906
Edward Evantash	officer: Chief Medical Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
John Dyett	director, 10 percent owner	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025
Adams John Q Jr	director	35 WYCK HILL LANE, WESTLAKE TX 76262
Edward R Uzialko	director, 10 percent owner	4605 DUDLEY LANE, ATLANTA GA 30327
Charles Larsen	director	28 SANDPIPER ROAD, TAMPA FL 33609
Kathy Lee-sepsick	director, officer: Chief Executive Officer	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Daniel Scott Currie	officer: Senior VP, Operations	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Kelley Hoskin Violet Alexandria	officer: VP, Clinical & Medical Affairs	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
Gary Thompson	director	3950 JOHNS CREEK COURT, SUITE 100, SUWANEE GA 30024
William Benson Witte	director	11111 SANTA MONICA BLVD., SUITE 2250, LOS ANGELES CA 90025